CJC-1295 + Ipamorelin Blend

Thorner, M. O., et al. (2009). Prolonged pharmacokinetic and pharmacodynamic profiles of CJC-1295, a long-acting growth hormone-releasing peptide, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 94(2), 589-597. / Sinha, S. P., et al. (2015). A comprehensive review on growth hormone secretagogues. Indian Journal of Endocrinology and Metabolism, 19(5), 629-635.

Timing is crucial to maximize the natural pulsatile release of growth hormone, particularly before sleep when natural GH release is highest, and potentially post-workout to support recovery.

• Exogenous Growth Hormone (HGH)

  Combining GHRPs/GHRHs with exogenous HGH is generally not recommended in research protocols as it can lead to supraphysiological GH levels and potentially increase side effects. The blend's purpose is to stimulate endogenous GH.

  Use Caution

• Somatostatin (Growth Hormone-Inhibiting Hormone)

  Somatostatin directly inhibits GH release. Agents that increase somatostatin activity would counteract the effects of CJC-1295 + Ipamorelin.

  Avoid

• Glucocorticoids (e.g., Dexamethasone)

  Glucocorticoids can suppress GH secretion. While not a direct contraindication, their use might diminish the effectiveness of the peptide blend, requiring careful monitoring in research.

  Monitor Combination

• Insulin

  Both GH and insulin affect glucose metabolism. While not a direct interaction in terms of peptide binding, concurrent use may necessitate careful monitoring of blood glucose levels, especially in individuals with metabolic sensitivities.

  Monitor Combination

• Thyroid Hormones

  No direct antagonistic interactions are commonly reported in research, and thyroid function is important for overall metabolism which GH influences. Compatible in research settings.

  Compatible

1. 1Gather supplies: Peptide vial, bacteriostatic water (diluent), sterile syringe (e.g., insulin syringe), alcohol wipes.
2. 2Remove the plastic cap from the peptide vial to expose the rubber stopper. Wipe the rubber stopper with an alcohol wipe.
3. 3Draw the desired amount of bacteriostatic water into the syringe. A common ratio is 1ml (100 units on an insulin syringe) per 2mg of peptide, but this can vary.
4. 4Slowly inject the bacteriostatic water into the peptide vial, aiming for the side of the vial, not directly onto the lyophilized powder.
5. 5Do NOT shake the vial. Gently swirl the vial or roll it between your palms to encourage the peptide to dissolve. This may take a few minutes.
6. 6Once fully dissolved, the solution should be clear. If any particles remain, continue swirling gently until completely dissolved.

Always handle peptides with sterile technique. Ensure all components (vial, syringe, diluent) are sterile.

• Weeks 1-4: May observe initial improvements in sleep quality, mood, and potentially increased energy levels. Some researchers report subtle improvements in recovery.
• Weeks 4-8: More noticeable effects on body composition may begin, such as slight reductions in fat mass and improved muscle tone. Enhanced recovery from physical activity is commonly discussed.
• Weeks 8-12: Peak benefits in body composition, including further fat reduction and lean muscle support, are often reported. Skin elasticity and overall vitality may show improvements.
• Beyond 12 weeks (if research protocols extend): Continued benefits may be observed, but some researchers suggest cycling for optimal response and to prevent potential desensitization.
• Throughout the cycle: Consistent improvements in exercise performance, endurance, and overall well-being are frequently cited in research contexts.